Anne Rancourt Named Director of Health Communication at FDA CTP

News by 2FIRSTS.ai
Apr.10.2024
Anne Rancourt Named Director of Health Communication at FDA CTP
Anne Rancourt named next director of CTP's Health Communication and Education Office by FDA, effective May 19.

The U.S. Food and Drug Administration (FDA) subsidiary Tobacco Products Center (CTP) recently announced that Anne Rancourt has been selected as the next director of the Office of Health Communication and Education. Rancourt previously served as the Communications Director at the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH).

 

Lungkul has over 20 years of experience in strategic communications, behavior change projects, and news fields, including nearly 14 years of work in the federal government. She managed the communication department at NIDA, overseeing the dissemination of research findings on substance use and addiction worth nearly $2 billion, including tobacco and e-cigarette use. Prior to this, she also served as the Chief of Communications Science at the National Institute of Allergy and Infectious Diseases (NIAID).

 

CTP stated that Lankhul has been selected after undergoing a thorough nationwide search and passing the important ethical and safety review process by the FDA. She will take office on May 19th.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT Expects Around 2% Revenue and Operating Profit Growth in FY25
BAT Expects Around 2% Revenue and Operating Profit Growth in FY25
British American Tobacco (BAT) reaffirmed its 2026 guidance while announcing a £1.3 billion (approximately USD 1.65 billion) share buyback for FY26. The company expects around 2% growth in revenue and adjusted profit from operations for FY25. Accelerating New Category growth, driven by Velo Plus and improving U.S. Vuse performance, is expected to deliver double-digit H2 revenue growth.
Dec.09 by 2FIRSTS.ai
Exclusive: Suspected ‘Backend Update Then Withdrawal’ Suggests Glas May Be Next FDA-Authorized E-Cigarette Brand After Juul
Exclusive: Suspected ‘Backend Update Then Withdrawal’ Suggests Glas May Be Next FDA-Authorized E-Cigarette Brand After Juul
An exclusive 2Firsts investigation found an unpublished FDA update on e-cigarette marketing authorizations that mirrors market speculation, suggesting Glas’s application may have cleared internal review, though no official confirmation has been issued.
Regulations
Dec.21
Product | Differences in Configuration and Indicator Methods: Three UWELL G5 Series Devices Launch on U.S. and U.K. Channels
Product | Differences in Configuration and Indicator Methods: Three UWELL G5 Series Devices Launch on U.S. and U.K. Channels
UWELL has launched three models in its Caliburn G5 Lite series across U.S. and U.K. channels, using indicator lights or breathing lights to display device status. Compared with the earlier G4 series, the new G5 Lite lineup continues a screenless design and increases battery capacity to 1,600mAh. The three devices also share the same core specifications, including e-liquid capacity, maximum power output, and pod compatibility.
Dec.10 by 2FIRSTS.ai
UK government letter agrees nicotine pouches are lower risk than smoking and a harm reduction tool
UK government letter agrees nicotine pouches are lower risk than smoking and a harm reduction tool
In correspondence with 20isPlenty campaigners, the government agreed nicotine pouches are likely to pose lower health risks than smoking and confirmed they are a harm reduction tool, while warning about their high nicotine content, fast absorption and potential to be flavoured.
Jan.06 by 2FIRSTS.ai
U.S. Washington State to Bring Synthetic Nicotine Under the Tobacco Tax System, Applying a Unified Tax Starting January 2026
U.S. Washington State to Bring Synthetic Nicotine Under the Tobacco Tax System, Applying a Unified Tax Starting January 2026
Washington State will subject all nicotine-containing products to the Tobacco Products Tax starting January 1, 2026, taxing them at 95% of the selling price. The change covers both tobacco-derived and synthetic nicotine products and requires businesses to report their inventory when the new tax system takes effect.
Dec.29 by 2FIRSTS.ai
Product | ON! PLUS: Breakdown of Six FDA-PMTA-Authorized Nicotine Pouches—6/9 mg Strengths, Slim Format, and Traditional Flavours
Product | ON! PLUS: Breakdown of Six FDA-PMTA-Authorized Nicotine Pouches—6/9 mg Strengths, Slim Format, and Traditional Flavours
The U.S. FDA has added six ON!® PLUS nicotine pouch products to its list of Marketing Granted Order (MGO) authorizations. Based on 2Firsts’ review, the approved products feature a highly standardized configuration in terms of format, nicotine strength, and flavour portfolio, primarily focusing on 6 mg and 9 mg strengths and traditional variants such as mint, wintergreen, and tobacco—reflecting a clear compliance-oriented approach.
Dec.22 by 2FIRSTS.ai